Crinetics Pharmaceuticals (CRNX) reported a Q3 net loss late Tuesday of $0.96 per diluted share, narrowing from a loss of $1.01 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.91.
No revenue was recorded for the quarter that ended Sept. 30, compared with $346,000 a year earlier. Analysts surveyed by Capital IQ projected $0.2 million.
The company said its cash, cash equivalents, and investment securities will be sufficient to fund its current operating plan into 2029.
Price: 60.00, Change: +1.14, Percent Change: +1.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments